Retatrutide: What you need to know about the triple hormone agonist
Medically reviewed by: Op. Dr. Ferhat İlen, ENT – Head & Neck Surgeon · Last updated:
Retatrutide is an investigational once-weekly injectable molecule targeting GLP-1, GIP, and glucagon receptors. Phase 2 trials demonstrated an average weight loss of approximately 24% at 48 weeks; Phase 3 results and regulatory approval processes are ongoing.
Regulatory / evidence status: Investigational drug developed by Eli Lilly, currently in Phase 3 (TRIUMPH). It is not licensed in any country.
How does it work?
The GLP-1 and GIP components reduce appetite and regulate insulin response. The glucagon component is aimed at increasing energy expenditure and hepatic lipid breakdown. This triple mechanism is the primary feature distinguishing it from tirzepatide and semaglutide.
Clinical data
In a Phase 2 trial published in the NEJM in 2023, an average weight loss of 24.2% was observed at 48 weeks with the highest dose.
The TRIUMPH Phase 3 clinical program is ongoing across areas including obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, and metabolic dysfunction-associated steatotic liver disease (MASLD).
Side effects and risks
The most common findings are nausea, vomiting, diarrhea, and constipation. Increased heart rate, lean muscle loss, and gallstone risks associated with rapid weight loss require clinical monitoring.
Because it remains unlicensed, the purity and actual contents of products sold on the market under the name 'retatrutide' cannot be verified.
Fi Life approach
Retatrutide is currently not a prescribable medication. At our clinic, approved treatment options for patients with metabolic goals are evaluated alongside lean muscle preservation and nutritional planning; we closely monitor new molecules alongside emerging scientific literature.
Frequently asked questions
Is retatrutide available in Turkey?
No. Retatrutide is not licensed in any country; it is currently only used within clinical trials.
How does it differ from tirzepatide?
Tirzepatide targets GLP-1 and GIP receptors, whereas retatrutide stimulates the glucagon receptor in addition to these two.
References
This page is for information only and does not replace diagnosis, treatment advice or a prescription. Peptide and drug assessments are made only after a physician consultation. No results are guaranteed.
Ask your physician whether it is right for you